Spravato® (Esketamine)
for Treatment-Resistant Depression

SPRAVATO®, an innovative treatment option offered by The Nexus Group, is a prescription nasal spray that contains esketamine. This fast-acting, FDA-approved medication can help adults with treatment-resistant depression find relief when other methods have not worked. If you choose to receive Spravato at The Nexus Group, you will receive expert care in a safe, supportive environment designed to help you regain control of your life.
‍
Unlike traditional antidepressants that target serotonin or norepinephrine, Spravato acts on the brain’s glutamate system. This unique mechanism allows it to provide more rapid relief for individuals who have not responded to other medications, making it especially suitable for those with treatment-resistant depression.

Your Spravato treatment will begin with a detailed consultation and assessment by our team. Once approved for Spravato, you will visit the office twice a week during the initial phase of treatment. At each session, you will self-administer the nasal spray in a comfortable clinical setting. Afterward, you will be observed for approximately two hours to monitor for any side effects. The Nexus care team will ensure you feel supported and safe throughout the process.

Over time, the frequency of sessions may be reduced based on your progress and how well your body responds. You will also have regular check-ins with your clinician so that your plan can be adjusted as needed. This level of personalized care helps maximize the effectiveness of Spravato and allows you to move forward with confidence.